S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
Log in

NASDAQ:PTEPolarityte Stock Price, Forecast & News

$0.90
-0.10 (-9.99 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.89
Now: $0.90
$1.02
50-Day Range
$0.88
MA: $1.28
$1.70
52-Week Range
$0.78
Now: $0.90
$11.45
Volume362,400 shs
Average Volume578,183 shs
Market Capitalization$34.53 million
P/E RatioN/A
Dividend YieldN/A
Beta2.06
PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTE
CUSIPN/A
CIKN/A
Phone385-237-2279

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.65 million
Book Value$1.42 per share

Profitability

Net Income$-92,490,000.00
Net Margins-1,636.46%

Miscellaneous

Employees123
Market Cap$34.53 million
Next Earnings DateN/A
OptionableOptionable

Receive PTE News and Ratings via Email

Sign-up to receive the latest news and ratings for PTE and its competitors with MarketBeat's FREE daily newsletter.


Polarityte (NASDAQ:PTE) Frequently Asked Questions

How has Polarityte's stock been impacted by COVID-19 (Coronavirus)?

Polarityte's stock was trading at $1.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PTE stock has decreased by 15.9% and is now trading at $0.9001. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Polarityte?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Polarityte in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Polarityte.

How were Polarityte's earnings last quarter?

Polarityte Inc (NASDAQ:PTE) released its earnings results on Tuesday, November, 12th. The company reported ($0.87) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.01) by $0.14. The company had revenue of $1.40 million for the quarter, compared to analysts' expectations of $1.41 million. Polarityte had a negative net margin of 1,636.46% and a negative return on equity of 169.50%. During the same period last year, the business earned ($0.86) EPS. View Polarityte's earnings history.

What price target have analysts set for PTE?

6 equities research analysts have issued 1 year price objectives for Polarityte's shares. Their forecasts range from $3.00 to $20.00. On average, they expect Polarityte's share price to reach $10.33 in the next twelve months. This suggests a possible upside of 1,048.0% from the stock's current price. View analysts' price targets for Polarityte.

Has Polarityte been receiving favorable news coverage?

Headlines about PTE stock have trended very negative recently, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Polarityte earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutPolarityte.

Are investors shorting Polarityte?

Polarityte saw a increase in short interest in March. As of March 13th, there was short interest totaling 3,960,000 shares, an increase of 10.0% from the February 27th total of 3,600,000 shares. Based on an average daily volume of 535,600 shares, the short-interest ratio is presently 7.4 days. Currently, 21.3% of the company's stock are short sold. View Polarityte's Current Options Chain.

Who are some of Polarityte's key competitors?

What other stocks do shareholders of Polarityte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Polarityte investors own include Acasti Pharma (ACST), Agile Therapeutics (AGRX), OrganiGram (OGI), Outlook Therapeutics (OTLK), SCYNEXIS (SCYX), Unum Therapeutics (UMRX), Nokia Oyj (NOK), Nabriva Therapeutics (NBRV), Amarin (AMRN) and Aytu Bioscience (AYTU).

Who are Polarityte's key executives?

Polarityte's management team includes the following people:
  • Dr. Denver M. Lough, Chairman, CEO and Chief R&D Officer (Age 38)
  • Mr. Paul Elliot Mann, Chief Financial Officer
  • Mr. Richard Hague, Chief Operating Officer (Age 59)
  • Dr. David Blum, Chief Design & Technology Officer
  • Mr. Nikolai Sopko, Chief Scientific Officer and VP of R&D

What is Polarityte's stock symbol?

Polarityte trades on the NASDAQ under the ticker symbol "PTE."

How do I buy shares of Polarityte?

Shares of PTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Polarityte's stock price today?

One share of PTE stock can currently be purchased for approximately $0.90.

How big of a company is Polarityte?

Polarityte has a market capitalization of $34.53 million and generates $5.65 million in revenue each year. The company earns $-92,490,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Polarityte employs 123 workers across the globe. View additional information about Polarityte.

What is Polarityte's official website?

The official website for Polarityte is http://www.polarityte.com/.

How can I contact Polarityte?

Polarityte's mailing address is 123 NORTH WRIGHT BROTHERS DRIVE, SALT LAKE CITY UT, 84116. The company can be reached via phone at 385-237-2279 or via email at [email protected]

This page was last updated on 4/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel